EGFR and non-small cell lung carcinoma: The third-generation EGFR TKIs osimertinib, olmutinib, rociletinib and others were designed to selectively and irreversibly target EGFR T790M as well as activating EGFR mutations, showing promising efficacy in NSCLC resistant to the first- and second-generation EGFR TKIs with lower toxicity observed in patients [12].